Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Antibe Therapeutics Inc(Pre-Merger) ATBPF

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.


GREY:ATBPF - Post by User

Comment by Forestviewon Feb 24, 2022 10:45am
92 Views
Post# 34457954

RE:RE:Another Last Chance

RE:RE:Another Last Chance Well said MadMonk.  Though the situation in Ukraine is far from comical, Dusty is keeping us entertained.  It's clear he wants to buy back in, and is hoping a mass panic (that he himself is trying to perpetrate) will drop this to $0.50. 




TheMadMonk wrote: Dusty, it is better to remain silent and be thought a fool than to take to your keyboard and remove all doubt.  Geopolitical factors like the Russia/Ukraine conflict do not affect stocks like ATE unless ATE was planning on moving their headoffice to Ukraine.  Sure big investors like you can sell your entire stake of 2000 shares in the hopes of buying them back a few pennies cheaper, laughing all the way to the bank with your $50 profit.  When you have a stock that trades only 50,000 shares per day, it is impossible to sell or buy a large position without affecting the stock price.  If you want to be a day trader, you should be doing it with a stock that has much higher trading volumes.  Please do us all a favour and stop coping and pasting every headline that you read on CNN.


<< Previous
Bullboard Posts
Next >>